Last reviewed · How we verify

Sulfamethazine (sulfadimidine)

Pfizer · FDA-approved active Quality 30/100

Sulfamethazine (generic name: sulfadimidine) is a sulfadimidine drug developed by Pfizer. It is currently FDA-approved (first approved 1949).

At a glance

Generic namesulfadimidine
SponsorPfizer
Drug classsulfadimidine
TargetLactoylglutathione lyase, Dihydropteroate synthase
Therapeutic areaImmunology
PhaseFDA-approved
First approval1949

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sulfamethazine

What is Sulfamethazine?

Sulfamethazine (sulfadimidine) is a sulfadimidine drug developed by Pfizer.

Who makes Sulfamethazine?

Sulfamethazine is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Sulfamethazine?

sulfadimidine is the generic (nonproprietary) name of Sulfamethazine.

What drug class is Sulfamethazine in?

Sulfamethazine belongs to the sulfadimidine class. See all sulfadimidine drugs at /class/sulfadimidine.

When was Sulfamethazine approved?

Sulfamethazine was first approved on 1949.

What development phase is Sulfamethazine in?

Sulfamethazine is FDA-approved (marketed).

What does Sulfamethazine target?

Sulfamethazine targets Lactoylglutathione lyase, Dihydropteroate synthase and is a sulfadimidine.

Related